Resorcylidene aminoguanidine induces antithrombotic action that is not dependent on its antiglycation activity

Vascular Pharmacology

Volumn 51, Issue 4, 2009, Pages 275-283

  Watala, Cezary ^a   Dobaczewski, Marcin ^a   Kazmierczak, Piotr ^a   Gebicki, Jerzy ^b   Nocun, Marek ^a   Zitnanova, Ingrid ^c   Ulicna, Olga ^c   Durackova, Zdena ^c   Waczulíková, Iveta ^d   Carsky, Jozef ^c   Chlopicki, Stefan ^e  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^c Faculty of Medicine ^*  (Slovakia)

^d Physics and Informatics   (Slovakia)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Antithrombotic effect; Carbonyl stress; Non enzymatic glycosylation; Resorcylidene aminoguanidine; Thromboxane generation; Vasoreactivity

Indexed keywords

11 OXOTHROMBOXANE B2; 2,5 DIHYDROXYBENZYLIDENE AMINOGUANIDINE; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; AMINOGUANIDINE; ANTICOAGULANT AGENT; BETA RESORCYLIDENE AMINOGUANIDINE; BOVINE SERUM ALBUMIN; C PEPTIDE; COLLAGEN; CYCLOOXYGENASE 2; HEPARIN; INDOMETACIN; INSULIN ZINC SUSPENSION; PROSTACYCLIN; PYRIDOXAL AMINOGUANIDINE; ROFECOXIB; SEPHAROSE; THROMBOXANE B2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTICOAGULATION; ANTIOXIDANT ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SYNTHESIS; EXTRACORPOREAL CIRCULATION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN GLYCOSYLATION; PROTEIN URINE LEVEL; RAT; STREPTOZOCIN DIABETES; STRUCTURE ACTIVITY RELATION; THROMBOCYTE AGGREGATION; THROMBOSIS; WISTAR RAT;

ANIMALS; CATTLE; FIBRINOLYTIC AGENTS; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; GUANIDINES; MALE; PROTEIN BINDING; RATS; RATS, WISTAR; SERUM ALBUMIN, BOVINE; THROMBOSIS;

EID: 70349981424     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2009.07.002     Document Type: Article

References (55)

1. Archibald V., Cotter M.A., Keegan A., and Cameron N.E. Contraction and relaxation of aortas from diabetic rats: effects of chronic anti-oxidant and aminoguanidine treatments. Naunyn Schmiedebergs Arch. Pharmacol. 353 (1996) 584-591
2. Boncler M.A., Golanski J., Paczuski R., and Watala C. Polymorphisms of glycoprotein Ib affect the inhibition by aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation. J. Mol. Med. 80 (2002) 796-801
3. Buss H., Chan T.P., Sluis K.B., Domigan N.M., and Winterbourn C.C. Protein carbonyl measurement by a sensitive ELISA method. Free Radic. Biol. Med. 23 (1997) 361-366
4. Cameron N.E., Gibson T.M., Nangle M.R., and Cotter M.A. Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes. Ann. N. Y. Acad. Sci. 1043 (2005) 784-792
5. Carsky J., Lazarova M., and Beno A. Study of resorcylidene aminoguanidine I. Spectral and acid-basic properties of the onium compounds. Acta Facultatis Rerum Naturalium Universitatis Comenianae. Chimia 26 (1978) 89-102
6. Ceriello A. Hyperglycaemia: the bridge between non-enzymatic glycation and oxidative stress in the pathogenesis of diabetic complications. Diabetes Nutr. Metab. 12 (1999) 42-46
7. Chen A.S., Taguchi T., Aoyama S., Sugiura M., Haruna M., Wang M.W., and Miwa I. Antioxidant activity of a Schiff base of pyridoxal and aminoguanidine. Free Radic. Biol. Med. 35 (2003) 1392-1403
8. Chlopicki S., and Gryglewski R.J. Angiotensin converting enzyme (ACE) and HydroxyMethylGlutaryl-CoA (HMG-CoA) reductase inhibitors in the forefront of pharmacology of endothelium. Pharmacol. Rep. 57 (2005) 86-96 Suppl
9. Chlopicki S., Swies J., Mogielnicki A., Buczko W., Bartus M., Lomnicka M., Adamus J., and Gebicki J. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br. J. Pharmacol. 152 (2007) 230-239
10. Davies M.G., and Hagen P.O. Alterations in venous endothelial cell and smooth muscle cell relaxation induced by high glucose concentrations can be prevented by aminoguanidine. J. Surg. Res. 63 (1996) 474-479
11. Dupin J.P., Gryglewski R.J., Gravier D., Hou G., Casadebaig F., Swies J., and Chlopicki S. Synthesis and thrombolytic activity of new thienopyrimidinone derivatives. J. Physiol. Pharmacol. 53 (2002) 625-634
12. Grosser T., Fries S., and FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Invest. 116 (2006) 4-15
13. Gryglewski R.J., Chlopicki S., and Swies J. In vivo endothelial interaction between ACE and COX inhibitors. Prostaglandins Leukot. Essent. Fat. Acids 72 (2005) 129-131
14. Gryglewski R.J., Korbut R., Ocetkiewicz A., and Stachura J. In vivo method for quantitation for anti-platelet potency of drugs. Naunyn Schmiedebergs Arch. Pharmacol. 302 (1978) 25-30
15. Gryglewski R.J., Uracz W., Swies J., Chlopicki S., Marcinkiewicz E., Lomnicka M., and Madej J. Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins. Ann. N. Y. Acad. Sci. 947 (2001) 229-245
16. Hanai T., Uchida M., Amao M., Ikeda C., Koizumi K., and Kinoshita T. Selective chemiluminescence analysis of amadori form of glycated human serum albumin. J. Liq. Chromatogr. Relat. Technol. 23 (2000) 3119-3131
17. Henle T., Deppisch R., Beck W., Hergesell O., Hansch G.M., and Ritz E. Advanced glycated end-products (AGE) during haemodialysis treatment: discrepant results with different methodologies reflecting the heterogeneity of AGE compounds. Nephrol. Dial. Transplant. 14 (1999) 1968-1975
18. Hovorka V., and Holzbecher Z. Metal salts of salicylaldehyde-tiosemicarbasone. Chem. Listy 45 (1951) 2-4
19. Hovorka V., Holzbecher Z., Moravek J., Vlacil F., and Zatka V. Asymmetric bicyclic inner complex compounds. Collection Czechoslov Chem. Commun. 18 (1953) 370-378
20. Hrnciarova M., Carsky J., Jakus V., Zlatos L., Kucharska J., and Gvozdjakova A. [Inhibition of lipid peroxidation in erythrocytes by aminoguanidine, resorcylidine aminoguanidine and their oxygen and sulfur analogs in diabetic rats]. Bratisl. Lek. Listy 99 (1998) 364-367
21. Jakus V., and Rietbrock N. Advanced glycation end-products and the progress of diabetic vascular complications. Physiol. Res. 53 (2004) 131-142
22. Jakus V., Hrnciarova M., Carsky J., Krahulec B., and Rietbrock N. Inhibition of nonenzymatic protein glycation and lipid peroxidation by drugs with antioxidant activity. Life Sci. 65 (1999) 1991-1993
23. Januszewski A.S., Alderson N.L., Metz T.O., Thorpe S.R., and Baynes J.W. Role of lipids in chemical modification of proteins and development of complications in diabetes. Biochem. Soc. Trans. 31 (2003) 1413-1416
24. Johnson R.N., Metcalf P.A., and Baker J.R. Fructosamine: a new approach to the estimation of serum glycosylprotein. An index of diabetic control. Clin. Chim. Acta 127 (1983) 87-95
25. Kalousova M., Skrha J., and Zima T. Advanced glycation end-products and advanced oxidation protein products in patients with diabetes mellitus. Physiol. Res. 51 (2002) 597-604
26. Kennedy A.L., and Lyons T.J. Glycation, oxidation, and lipoxidation in the development of diabetic complications. Metabolism 46 (1997) 14-21
27. Khatami M., Suldan Z., David I., Li W., and Rockey J.H. Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation. Life Sci. 43 (1988) 1725-1731
28. Korytar P., Sivonova M., Maruniakova A., Ulicna O., Kvasnicka P., Liptakova A., Bozek P., Carsky J., and Durackova Z. Influence of 2,5-dihydroxybenzylidene aminoguanidine on lipid oxidative damage and on antioxidant levels in model diabetes mellitus. Pharmazie 58 (2003) 733-737
29. Labieniec M., Przygodzki T., Carsky J., Malinska D., Rysz J., and Watala C. Effects of resorcylidene aminoguanidine (RAG) on selected parameters of isolated rat liver mitochondria. Chem. Biol. Interact. 179 (2008) 280-287
30. Lellouche F., Fradin A., Fitzgerald G., and Maclouf J. Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin. Prostaglandins 40 (1990) 297-310
31. Liptakova A., Carsky J., Ulicna O., Vancova O., Bozek P., and Durackova Z. Influence of beta-resorcylidene aminoguanidine on selected metabolic parameters and antioxidant status of rats with diabetes mellitus. Physiol. Res. 51 (2002) 277-284
32. Miyata T. Alterations of non-enzymatic biochemistry in uremia, diabetes, and atherosclerosis ("carbonyl stress"). Bull. Mem. Acad. R. Med. Belg. 157 (2002) 189-196
33. Miyata T., Ishikawa N., and van Ypersele d.S. Carbonyl stress and diabetic complications. Clin. Chem. Lab. Med. 41 (2003) 1150-1158
34. Miyoshi H., Taguchi T., Sugiura M., Takeuchi M., Yanagisawa K., Watanabe Y., Miwa I., Makita Z., and Koike T. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. Horm. Metab. Res. 34 (2002) 371-377
35. Munch G., Keis R., Wessels A., Riederer P., Bahner U., Heidland A., Niwa T., Lemke H.D., and Schinzel R. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur. J. Clin. Chem. Clin. Biochem. 35 (1997) 669-677
36. Murphy R.C., and FitzGerald G.A. Current approaches to estimation of eicosanoid formation in vivo. Adv. Prostaglandin Thromboxane Leukot Res. 22 (1994) 341-348
37. Nilsson B.O. Biological effects of aminoguanidine: an update. Inflamm. Res. 48 (1999) 509-515
38. Nocun M., Golanski J., Lapshina E., Zavodnik L., Dobaczewski M., Kazmierczak P., Markuszewski L., Zavodnik I., and Watala C. Usefulness of whole blood aggregometry and its comparison with thromboxane generation assay in monitoring acetylsalicylic acid effectiveness - a multiparametric study in rats. Clin. Chem. Lab. Med. 44 (2006) 653-662
39. Sashidhar R.B., Capoor A.K., and Ramana D. Quantitation of epsilon-amino group using amino acids as reference standards by trinitrobenzene sulfonic acid. A simple spectrophotometric method for the estimation of hapten to carrier protein ratio. J. Immunol. Methods 167 (1994) 121-127
40. Sies H. Oxidative Stress: Oxidants and Antioxidants., London (2005)
41. Sitte N., Merker K., and Grune T. Proteasome-dependent degradation of oxidized proteins in MRC-5 fibroblasts. FEBS Lett. 440 (1998) 399-402
42. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., and Klenk D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150 (1985) 76-85
43. Stankoviansky S., and Carsky J. Metalsalts of resorcylidene thiosemicarbasone [II]. Chem. Zvesti. 15 (1961) 131-135
44. Taguchi T., Sugiura M., Hamada Y., and Miwa I. Inhibition of advanced protein glycation by a Schiff base between aminoguanidine and pyridoxal. Eur. J. Pharmacol. 378 (1999) 283-289
45. Thornalley P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch. Biochem. Biophys. 419 (2003) 31-40
46. Vlassara H., and Palace M.R. Diabetes and advanced glycation endproducts. J. Intern. Med. 251 (2002) 87-101
47. Vlassara H., and Palace M.R. Glycoxidation: the menace of diabetes and aging. Mt. Sinai J. Med. 70 (2003) 232-241
48. Waczulikova I., Sikurova L., Bryszewska M., kawiecka R., Carsky J., and Ulicna O. Impaired erythrocyte transmembrane potential in diabetes mellitus and its possible improvement by resorcylidene aminoguanidine. Bioelectrochemistry 52 (2000) 251-256
49. Waczulikova I., Sikurova L., Carsky J., Strbova L., and Krahulec B. Decreased fluidity of isolated erythrocyte membranes in type 1 and type 2 diabetes. The effect of resorcylidene aminoguanidine. Gen. Physiol. Biophys. 19 (2000) 381-392
50. Waczulikova I., Sikurova L., and Carsky J. Fluidity gradient of erythrocyte membranes in diabetics: the effect of resorcylidene aminoguanidine. Bioelectrochemistry 55 (2002) 53-55
51. 2+ overload. J. Physiol. Pharmacol. 53 (2002) 727-739
52. Watala C., Pluta J., Golanski J., Rozalski M., Czyz M., Trojanowski Z., and Drzewoski J. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J. Mol. Med. 83 (2005) 148-158
53. Watala C., Ulicna O., Golanski J., Nocun M., Waczulikova I., Markuszewski L., and Drzewoski J. High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study. Blood Coagul. Fibrinolysis. 17 (2006) 113-124
54. Whitehead T.P., Jungner I., Robinson D., Kolar W., Pearl A., and Hale A. Serum urate, serum glucose and diabetes. Ann. Clin. Biochem. 29 Pt 2 (1992) 159-161
55. Zar J. Biostatistical Analysis (1999), Prentice-Hall International, Inc.